MIRBUE Trademark

Trademark Overview


On Wednesday, June 22, 2022, a trademark application was filed for MIRBUE with the United States Patent and Trademark Office. The USPTO has given the MIRBUE trademark a serial number of 97469857. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Thursday, June 20, 2024. This trademark is owned by Eli Lilly and Company. The MIRBUE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascula...
mirbue

General Information


Serial Number97469857
Word MarkMIRBUE
Filing DateWednesday, June 22, 2022
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateThursday, June 20, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 9, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateThursday, June 20, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Saturday, June 25, 2022NEW APPLICATION ENTERED
Saturday, July 9, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, April 4, 2023ASSIGNED TO EXAMINER
Thursday, April 6, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 19, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 9, 2023PUBLISHED FOR OPPOSITION
Tuesday, May 9, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 4, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, December 18, 2023SOU TEAS EXTENSION RECEIVED
Monday, December 18, 2023SOU EXTENSION 1 FILED
Monday, December 18, 2023SOU EXTENSION 1 GRANTED
Wednesday, December 20, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 19, 2024TEAS EXPRESS ABANDONMENT RECEIVED
Thursday, June 20, 2024ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Thursday, June 20, 2024ABANDONMENT - AFTER PUBLICATION